RxDoctor Payments DataLook up a doctor →

Shaila Gogate, MD

Allergy & Immunology · Denver, CONPI 1629124235

Payments from drug & device makers

$4,030,142in general payments, 2019–2025

Across 573 payments — averaging $7033.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.1M
  • AstraZeneca$1.1M
  • Teva Pharmaceuticals USA, Inc.$454K
  • Cipla USA Inc.$260K
  • Hikma Pharmaceuticals USA$232K
  • GSK$228K
  • plus $598K from 26 others
$2,914in research payments, 2019–2025

Across 5 payments — averaging $582.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Chiesi USA, Inc.$2K
  • Novartis$616
  • Teva Pharmaceuticals USA, Inc.$87

What the payments were for

  • Consulting fees$16,58880%
  • Travel & lodging$1,4277%
  • Food & beverage$2,62113%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,030,142 in reported general payments places this provider in the 95th percentile of 89 allergy & immunology providers in Colorado.

See all allergy & immunology providers in Colorado

Medicare billing

Part B allowed, 2024
$202,372
Medicare patients
449
Services billed
11,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$29,591
SymbicortBudesonide/Formoterol Fumarate66$24,416
Advair HfaFluticasone Propion/Salmeterol36$13,332
Spiriva RespimatTiotropium Bromide21$12,376
Fluticasone-SalmeterolFluticasone Propion/Salmeterol59$6,834
Breo ElliptaFluticasone/Vilanterol11$5,307
Qvar RedihalerBeclomethasone Dipropionate17$4,439
Ipratropium Bromide102$4,094
Epinephrine12$2,806
Albuterol Sulfate HfaAlbuterol Sulfate67$1,761
Montelukast Sodium55$943
BreynaBudesonide/Formoterol Fumarate15$767
Azelastine Hcl15$418
Levocetirizine Dihydrochloride21$216
Prednisone20$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$228,190$34,89842 claims
AstraZenecaSymbicort$1,126,469$24,41666 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$453,945$4,43917 claims
Hikma Pharmaceuticals USAEpinephrine$232,379$2,80612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 89 allergy & immunology providers in Colorado.

Other allergy & immunology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →